Insulin-like growth factor binding proteins: A structural perspective

Frontiers in Endocrinology

Volumn 3, Issue MAR, 2012, Pages

  Forbes, Briony E ^a   McCarthy, Peter ^a   Norton, Raymond S ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

IGF binding protein; Insulin like growth factor; Protein structure

Indexed keywords

EID: 84865389373     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00038     Document Type: Article

References (124)

1. Arai, T., Busby, W. Jr., and Clemmons, D. R. (1996a). Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 137,4571-4575.
2. Arai, T., Clarke, J., Parker, A., Busby, W. Jr., Nam, T., and Clemmons, D. R. (1996b). Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin. J. Biol Chem. 271,6099-6106.
3. Arai, T., Parker, A., Busby, W. Jr., and Clemmons, D. R. (1994). Heparin, heparan sulfate, and der-matan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J. Biol Chem. 269,20388-20393.
4. Azar, W. J., Azar, S. H., Higgins, S., Hu, J. F., Hoffman, A. R., Newgreen, D. F., Werther, G. A., and Russo, V. C. (2011). IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells. Endocrinology 152,3332-3342.
5. Bach, L. A., Headey, S. J., and Norton, R. S. (2005).IGF-bindingproteins-the pieces are falling into place. Trends Endocrinol. Metab. 16,228-234.
6. Berg, U., Bang, P., and Carlsson-Skwirut, C. (2007). Calpain proteolysis of insulin-like growth factor binding protein (IGFBP) -2 and -3, but not of IGFBP-1. Biol. Chem. 388, 859-863.
7. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000). The protein data bank. Nucleic Acids Res. 28,235-242.
8. Boes, M., Booth, B. A., Sandra, A., Dake, B. L., Bergold, A., and Bar, R. S. (1992). Insulin-like growth factor binding protein (IGFBP)4 accounts for the connective tissue distribution of endothelial cell IGFBPs perfused through the isolated heart. Endocrinology 131, 327-330.
9. Boisclair, Y. R., Rhoads, R. P., Ueki, I., Wang, J., and Ooi, G. T. (2001). The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J. Endocrinol. 170, 63-70.
10. Boldt, H. B., and Conover, C. A. (2007). Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm. IGF Res. 17,10-18.
11. Booth, B. A., Boes, M., Andress, D. L., Dake, B. L., Kiefer, M. C., Maack, C., Linhardt, R. J., Bar, K., Caldwell, E. E., Weiler, J., and Bar, R. S. (1995). IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul. 5, 1-17.
12. Brown, J., Jones, E. Y., and Forbes, B. E. (2009). Keeping IGF-II under control: lessons from the IGF-II-IGF2R crystal structure. Trends Biochem. Sci. 34, 612-619.
13. Brzozowski, A. M., Dodson, E. J., Dod-son, G. G., Murshudov, G. N.,Verma, C., Turkenburg, J. P., De Bree, F. M., and Dauter, Z. (2002). Structural origins of the functional divergence of human insulin-like growth factor-I and insulin. Biochemistry 41, 9389-9397.
14. Bunn, R. C., and Fowlkes, J. L. (2003). Insulin-like growth factor binding protein proteolysis. Trends Endocrinol. Metab. 14, 176-181.
15. Carrick, F. E., Forbes, B. E., and Wallace, J. C. (2001). BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains. J. Biol. Chem. 276,27120-27128.
16. Carrick, F. E., Hinds, M. G., McNeil, K. A., Wallace, J. C., Forbes, B. E., and Norton, R. S. (2005). Interaction of insulin-like growth factor (IGF)-I and -II with IGF binding protein-2: mapping the binding surfaces by nuclear magnetic resonance. J. Mol. Endocrinol. 34, 685-698.
17. Chandrashekaran, I. R., Yao, S., Wang, C. C., Bansal, P. S., Alewood, P. F., Forbes, B. E., Wallace, J. C., Bach, L. A., and Norton, R. S. (2007). The N-terminal subdomain of insulin-like growth factor (IGF) binding protein 6. Structure and interaction with IGFs. Biochemistry 46, 3065-3074.
18. Chelius, D., Baldwin, M. A., Lu, X., and Spencer, E. M. (2001). Expression, purification and characterization of the structure and disulfide linkages of insulin-like growth factor binding protein-4. J. Endocrinol. 168,283-296.
19. Clemmons, D. R. (2001). Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr. Rev. 22, 800-817.
20. Clemmons, D. R. (2007). Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat. Rev. Drug Discov. 6, 821-833.
21. Conover, C. A. (2010). PAPP-A: a new anti-aging target? Aging Cell 9, 942-946.
22. Conover, C. A., Bale, L. K., Overgaard, M. T., Johnstone, E. W., Laursen, U. H., Fuchtbauer, E. M., Oxvig, C., and Van Deursen, J. (2004). Met-alloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 131,1187-1194.
23. Conover, C. A., Boldt, H. B., Bale, L. K., Clifton, K. B., Grell, J. A., Mader, J. R., Mason, E. J., and Powell, D. R. (2011). Pregnancy-associated plasma protein-A2 (PAPP-A2): tissue expression and biological consequences of gene knockout in mice. Endocrinology 152,2837-2844.
24. Conover, C. A., Durham, S. K., Zapf, J., Masiarz, F. R., and Kiefer, M. C. (1995). Cleavage analysis of insulin-like growth factor (IGF)-dependent IGF-binding protein-4 proteolysis and expression of protease-resistant IGF-binding protein-4 mutants. J. Biol. Chem. 270, 4395-4400.
25. Conover, C. A., Kiefer, M. C., and Zapf, J. (1993). Posttranslational regulation of insulin-like growth factor binding protein-4 in normal and transformed human fibroblasts. Insulin-like growth factor dependence and biological studies. J. Clin. Invest. 91, 1129-1137.
26. Coverley, J. A., Martin, J. L., and Baxter, R. C. (2000). The effect of phosphorylation by casein kinase 2 on the activity of insulin-like growth factor-binding protein-3. Endocrinology 141, 564-570.
27. Cui, J., Ma, C., Qiu, J., Ma, X., Wang, X., Chen, H., and Huang, B. (2011). A novel interaction between insulin-like growth factor binding protein-6 and the vitamin D receptor inhibits the role of vitamin D3 in osteoblast differentiation. Mol. Cell. Endocrinol. 338, 84-92.
28. Damon, S. E., Maddison, L., Ware, J. L., and Plymate, S. R. (1998). Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology 139, 3456-3464.
29. Denley A., Cosgrove, L. J., Booker, G. W., Wallace, J. C., and Forbes, B. E. (2005a). Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 16,421-439.
30. Denley, A., Wang, C. C., McNeil, K. A., Walenkamp, M. J., Van Duyven-voorde, H., Wit, J. M., Wallace, J. C., Norton, R. S., Karperien, M., and Forbes, B. E. (2005b). Structural and functional characteristics of the Val44Met insulin-like growth factor I missense mutation: correlation with effects on growth and development. Mol. Endocrinol. 19, 711-721.
31. Denley, A., Wallace, J. C., Cosgrove, L. J., and Forbes, B. E. (2003). The insulin receptor isoform exon 11-(IR-A) in cancer and other diseases: a review. Horm. Metab. Res. 35, 778-785.
32. Dolcini, L., Sala, A., Campagnoli, M., Labo, S., Valli, M., Visai, L., Min-chiotti, L., Monaco, H. L., and Galliano, M. (2009). Identification of the amniotic fluid insulin-like growth factor binding protein-1 phosphorylation sites and propensity to proteolysis of the isoforms. FEBS J.276,6033-6046.
33. Domene, H. M., Hwa, V., Jasper, H. G., and Rosenfeld, R. G. (2011). Acid-labile subunit (ALS) deficiency. Best Pract. Res. Clin. Endocrinol. Metab. 25, 101-113.
34. Duan, C., and Xu, Q. (2005). Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen. Comp. Endocrinol. 142, 44-52.
35. Firth, S. M., and Baxter, R. C. (1999). Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J. Endocrinol. 160,379-387.
36. Firth, S. M., and Baxter, R. C. (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23, 824-854.
37. Firth, S. M., Ganeshprasad, U., and Baxter, R. C. (1998). Structural determinants of ligand and cell surface binding of insulin-like growth factor-bindingprotein-3.J. Biol.Chem.273, 2631-2638.
38. Forbes, B. E., Turner, D., Hodge, S. J., McNeil, K. A., Forsberg, G., and Wallace, J. C. (1998). Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain. J. Biol. Chem. 273, 4647-4652.
39. Fowlkes, J. L., and Serra, D. M. (1996). Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3. J. Biol Chem. 271, 14676-14679.
40. Fowlkes, J. L., Thrailkill, K. M., George-Nascimento, C., Rosenberg, C. K., and Serra, D. M. (1997). Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation. Endocrinology 138,2280-2285.
41. Francis, G. L., Ross, M., Ballard, F. J., Milner, S. J., Senn, C., McNeil, K. A., Wallace, J. C., King, R., and Wells, J. R. (1992). Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J. Mol Endocrinol. 8, 213-223.
42. Fu, P., Thompson, J. A., and Bach, L. A. (2007). Promotion of cancer cell migration: an insulin-like growth factor (IGF)-independent action of IGF-binding protein-6. J. Biol. Chem. 282, 22298-22306.
43. Galanis, M., Firth, S. M., Bond, J., Nathanielsz, A., Kortt, A. A., Hudson, P. J., and Baxter, R. C. (2001). Ligand-binding characteristics of recombinant amino-and carboxyl-terminal fragments of human insulin-like growth factor- binding protein-3.J. Endocrinol. 169, 123-133.
44. Galea, C. A., Mobli, M., McNeil, K. A., Mulhern, T. D., Wallace, J. C., King, G. F., Forbes, B. E., and Norton, R. S. (2012). Insulin-like growth factor binding protein-2: NMR analysis and structural characterization of the N-terminal domain. Biochimie 94, 608-616.
45. Gallicchio, M. A., Kneen, M., Hall, C., Scott, A. M., and Bach, L. A. (2001). Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. Int. J. Cancer 94, 645-651.
46. Gibson, J. M.,Aplin, J. D., White, A., and Westwood, M. (2001). Regulation of IGF bioavailability in pregnancy. Mol. Hum. Reprod. 7, 79-87.
47. Gleeson, L. M., Chakraborty, C., Mck-innon, T., and Lala, P. K. (2001). Insulin-like growth factor-binding protein 1 stimulates human tro-phoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein Kinase pathway. J. Clin. Endocrinol. Metab. 86, 2484-2493.
48. Graham, M. E., Kilby, D. M., Firth, S. M., Robinson, P. J., and Baxter, R. C. (2007). The in vivo phosphorylation and glycosylation of human insulin-like growth factor-binding protein-5. Mol. Cell Proteomics 6, 1392-1405.
49. Gyrup, C., and Oxvig, C. (2007). Quantitative analysis of insulin-like growth factor-modulated proteolysis of insulin-like growth factor binding protein-4 and -5 by pregnancy-associated plasma protein-A. Biochemistry 46, 1972-1980.
50. Hajduk, P. J., and Greer, J. (2007). A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6,211-219.
51. Headey, S. J., Keizer, D. W., Yao, S., Brasier, G., Kantharidis, P., Bach, L. A., and Norton, R. S. (2004a). C-terminal domain of insulin-like growth factor binding protein-6: structure and interaction with insulin-like growth factor-II. Mol. Endocrinol. 18,2740-2750.
52. Headey, S. J., Keizer, D. W., Yao, S., Wallace, J. C., Bach, L. A., and Norton, R. S. (2004b). Binding site for the C-domain of insulin-like growth factor (IGF) binding protein-6 on IGF-II; implications for inhibition of IGF actions. FEBS Lett. 568, 19-22.
53. Headey, S. J., Leeding, K. S., Norton, R. S., and Bach, L. A. (2004c). Contributions of the N- and C-terminal domains of IGF binding protein-6 to IGF binding. J. Mol. Endocrinol. 33, 377-386.
54. Ho, P. J., and Baxter, R. C. (1997). Characterization of truncated insulin-like growth factor-binding protein-2 in human milk. Endocrinology 138, 3811-3818.
55. Hobba, G. D., Forbes, B. E., Parkinson, E. J., Francis, G. L., and Wallace, J. C. (1996). The insulin-like growth factor (IGF) binding site of bovine insulin-like growth factor binding protein-2 (bIGFBP-2) probed by iodination. J. Biol. Chem. 271,30529-30536.
56. Hobba, G. D., Lothgren, A., Holm-berg, E., Forbes, B. E., Francis, G. L., and Wallace, J. C. (1998). Ala-nine screening mutagenesis establishes tyrosine 60 of bovine insulin-like growth factor binding protein-2 as a determinant of insulin-like growth factor binding. J. Biol. Chem. 273,19691-19698.
57. Hollier, B. G., Kricker, J. A., Van Lonkhuyzen, D. R., Leavesley, D. I., and Upton, Z. (2008). Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coacti-vation of the phosphatidylinositide 3-Kinase/AKT pathway by alphav-integrins and the IGF-I receptor. Endocrinology 149, 1075-1090.
58. Holman, S. R., and Baxter, R. C. (1996). Insulin-like growth factor binding protein-3: factors affecting binary and ternary complex formation. Growth Regul. 6, 42-47.
59. Horney, M. J., Evangelista, C. A., and Rosenzweig, S. A. (2001). Synthesis and characterization of insulin-like growth factor (IGF)-1 photoprobes selective for the IGF-binding proteins (IGFBPS). Photoaffinity labeling of the IGF-binding domain on IGFBP-2. J. Biol. Chem. 276, 2880-2889.
60. Huq, A., Singh, B., Meeker, T., and Mascarenhas, D. (2009). The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells. Anticancer Drugs 20,21-31.
61. Imai, Y., Moralez, A., Andag, U., Clarke, J. B., Busby, W H. Jr., and Clem-mons, D. R. (2000). Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions. J. Biol. Chem.275, 18188-18194.
62. Iosef, C., Gkourasas, T., Jia, C. Y., Li, S. S., and Han, V. K. (2008). A functional nuclear localization signal in insulin-like growth factor binding protein-6 mediates its nuclear import. Endocrinology 149, 1214-1226.
63. Janosi, J. B., Firth, S. M., Bond, J. J., Baxter, R. C., and Delhanty, P. J. (1999). N-Linked glycosylation and sialylation of the acid-labile subunit. Role in complex formation with insulin-like growth factor (IGF)-binding protein-3 and the IGFs. J. Biol. Chem. 274, 5292-5298.
64. Jones, J. I., Busby, W H. Jr., Wright, G., Smith, C. E., Kimack, N. M., and Clemmons, D. R. (1993a). Identification of the sites of phosphorylation in insulin-like growth factor binding protein-1. Regulation of its affinity by phosphorylation of serine 101.J. Biol. Chem. 268, 1125-1131.
65. Jones, J. I., Gockerman, A., Busby, W H. Jr., Camacho-Hubner, C., and Clemmons, D. R. (1993b). Extracellular matrix contains insulin-like growth factor binding protein-5: potentia-tion of the effects of IGF-I. J. Cell Biol. 121, 679-687.
66. Jones, J. I., Gockerman, A., Busby, W. H. Jr., Wright, G., and Clemmons, D. R. (1993c). Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc. Natl. Acad. Sci. U.S.A. 90, 10553-10557.
67. Kainosho, M., Torizawa, T., Iwashita, Y., Terauchi, T., Mei Ono, A., and Guntert, P. (2006). Optimal isotope labelling for NMR protein structure determinations. Nature 440, 52-57.
68. Kalus, W., Zweckstetter, M., Renner, C., Sanchez, Y., Georgescu, J., Grol, M., Demuth, D., Schumacher, R., Dony, C., Lang, K., and Holak, T. A. (1998). Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J. 17, 6558-6572.
69. Kricker, J. A., Hyde, C. E., Van Lonkhuyzen, D. R., Hollier, B. G., Shooter, G. K., Leavesley, D. I., Herington, A. C., and Upton, Z. (2010). Mechanistic investigations into interactions between IGF-I and IGFBPs and their impact on facilitating cell migration on vitronectin. Growth Factors 28, 359-369.
70. Kricker, J. A., Towne, C. L., Firth, S. M., Herington, A. C., and Upton, Z. (2003). Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology 144, 2807-2815.
71. Kuang, Z., Yao, S., Keizer, D. W., Wang, C. C., Bach, L. A., Forbes, B. E., Wallace, J. C., and Norton, R. S. (2006). Structure, dynamics and heparin binding of the C-terminal domain of insulin-like growth factor-binding protein-2 (IGFBP-2). J. Mol. Biol. 364, 690-704.
72. Kuang, Z., Yao, S., McNeil, K. A., Thompson, J. A., Bach, L. A., Forbes, B. E., Wallace, J. C., and Norton, R. S. (2007). Cooperativity of the N- and C-terminal domains of insulin-like growth factor (IGF) binding protein 2 in IGF binding. Biochemistry 46, 13720-13732.
73. Laursen, L. S., Overgaard, M. T., Soe, R., Boldt, H. B., Sottrup-Jensen, L., Giudice, L. C., Conover, C. A., and Oxvig, C. (2001). Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Lett. 504, 36-40.
74. Lee, Y. C., Jogie-Brahim, S., Lee, D. Y., Han, J., Harada, A., Murphy, L. J., and Oh, Y (2011). Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-kappaB signaling through IGFBP-3R-mediated activation of caspases. J. Biol. Chem. 286, 17898-17909.
75. Lewitt, M. S., Saunders, H., Phuyal, J. L., and Baxter, R. C. (1994). Complex formation by human insulin-like growth factor-binding protein-3 and human acid-labile subunit in growth hormone-deficient rats. Endocrinology 134, 2404-2409.
76. Liu,B.,Lee, H.Y.,Weinzimer,S. A., Powell, D. R., Clifford, J. L., Kurie, J. M., and Cohen, P. (2000). Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J. Biol. Chem. 275, 33607-33613.
77. Mark, S., Kubler, B., Honing, S., Oester-reicher, S., John, H., Braulke, T., Forssmann, W. G., and Stand-ker, L. (2005). Diversity of human insulin-like growth factor (IGF) binding protein-2 fragments in plasma: primary structure, IGF-binding properties, and disulfide bonding pattern. Biochemistry 44, 3644-3652.
78. McCusker, R. H. (1998). Controlling insulin-like growth factor activity and the modulation of insulin-like growth factor binding protein and receptor binding. J. Dairy Sci. 81, 1790-1800.
79. Mendes, K. N., Wang, G. K., Fuller, G. N., and Zhang, W. (2010). JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration. Int. J. Oncol. 37, 143-153.
80. Miyako, K., Cobb, L. J., Francis, M., Huang, A., Peng, B., Pintar, J. E., Ariga, H., and Cohen, P. (2009). PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol. Endocrinol. 23, 169-175.
81. Miyamoto, S., Nakamura, M., Yano, K., Ishii, G., Hasebe, T., Endoh, Y., San-gai, T., Maeda, H., Shi-Chuang, Z., Chiba, T., and Ochiai, A. (2007). Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix. Cancer Sci. 98, 685-691.
82. Monget, P., Mazerbourg, S., Delpuech, T., Maurel, M. C., Maniere, S., Zapf, J., Lalmanach, G., Oxvig, C., and Overgaard, M. T. (2003). Pregnancy-associated plasma protein-A is involved in insulin-like growth factor binding protein-2 (IGFBP-2) proteolytic degradation in bovine and porcine preovulatory follicles: identification of cleavage site and characterization of IGFBP-2 degradation. Biol. Reprod. 68, 77-86.
83. Nam, T. J., Busby, W. Jr., and Clemmons, D. R. (1997). Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I. Endocrinology 138, 2972-2978.
84. Neumann, G.M., and Bach, L. A. (1999). The N-terminal disulfide linkages of human insulin-like growth factor-binding protein-6 (hIGFBP-6) and hIGFBP-1 are different as determined by mass spectrometry. J. Biol. Chem. 274,14587-14594.
85. Neumann, G. M., Marinaro, J. A., and Bach, L. A. (1998). Identification of O-glycosylation sites and partial characterization of carb ohydrate structure and disulfide linkages of human insulin-like growth factor binding protein 6. Biochemistry 37, 6572-6585.
86. Ning, Y., Schuller, A. G., Conover, C. A., and Pintar, J. E. (2008). Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo. Mol. Endocrinol. 22, 1213-1225.
87. Paharkova-Vatchkova, V., and Lee, K. W. (2010). Nuclear export and mito-chondrial and endoplasmic retic-ulum localization of IGF-binding protein 3 regulate its apoptotic properties. Endocr. Relat. Cancer 17, 293-302.
88. Payet, L. D., Firth, S. M., and Baxter, R. C. (2004). The role of the acid-labile subunit in regulating insulin-like growth factor transport across human umbilical vein endothelial cell monolayers. J. Clin. Endocrinol. Metab. 89, 2382-2389.
89. Payet, L. D., Wang, X. H., Baxter, R. C., and Firth, S. M. (2003). Amino-and carboxyl-terminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to bind IGFs with high affinity and inhibit IGF receptor interactions. Endocrinology 144, 2797-2806.
90. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004). UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612.
91. Piriz, J., Muller, A., Trejo, J. L., and Torres-Aleman, I. (2011). IGF-I and the aging mammalian brain. Exp. Gerontol. 46, 96-99.
92. Pollak, M. (2008a). Insulin and insulin-like growth factor signalling in neo-plasia. Nat. Rev. Cancer 8, 915-928.
93. Pollak, M. (2008b). Targeting insulin and insulin-like growth factor signalling in oncology. Curr. Opin. Pharmacol. 8, 384-392.
94. Qin, X., Strong, D. D., Baylink, D. J., and Mohan, S. (1998a). Structure-function analysis of the human insulin-like growth factor binding protein-4. J. Biol. Chem. 273, 23509-23516.
95. Qin, X., Strong, D. D., Baylink, D. J., and Mohan, S. (1998b). Structure-function analysis of the human insulin-like growth factor binding protein-4. J. Biol. Chem. 273, 23509-23516.
96. Regan, F. M., Williams, R. M., Mcdon-ald, A., Umpleby, A. M., Acerini, C. L., O'Rahilly, S., Hovorka, R., Semple, R. K., and Dunger, D. B. (2010). Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance. J. Clin. Endocrinol. Metab. 95, 2113-2122.
97. Rehault, S., Monget, P., Mazerbourg, S., Tremblay, R., Gutman, N., Gauthier, E, and Moreau, T. (2001). Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur. J. Biochem. 268, 2960-2968.
98. Rosenfeld, R. G. (2007). IGF-I therapy in growth disorders. Eur. J. Endocrinol. 157, S57-S60.
99. Rosenzweig, S. A., and Atreya, H. S. (2010). Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem. Pharmacol. 80, 1115-1124.
100. Russo, V. C., Schutt, B. S., Andaloro, E., Ymer, S. I., Hoeflich, A., Ranke, M. B., Bach, L. A., and Werther, G. A. (2005). Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146,4445-4455.
101. Ryan, A. J., Napoletano, S., Fitzpatrick, P. A., Currid, C. A., O'Sullivan, N. C., and Harmey, J. H. (2009). Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer. Br. J. Cancer 101,278-286.
102. Sala, A., Capaldi, S., Campagnoli, M., Faggion, B., Labo, S., Perduca, M., Romano, A., Carrizo, M. E., Valli, M., Visai, L., Minchiotti, L., Galliano, M., and Monaco, H. L. (2005). Structure and properties of the C-terminal domain of insulin-like growth factor-binding protein-1 isolated from human amniotic fluid. J. Biol. Chem. 280,29812-29819.
103. Schedlich, L. J., Young, T. F., Firth, S. M., and Baxter, R. C. (1998). Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J. Biol. Chem. 273, 18347-18352.
104. Schutt, B. S., Langkamp, M., Rauschn-abel, U., Ranke, M. B., and Elmlinger, M. W (2004). Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J. Mol. Endocrinol. 32, 859-868.
105. Singh, B., Charkowicz, D., and Mas-carenhas, D. (2004). Insulin-like growth factor-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3. J. Biol. Chem. 279, 477-487.
106. Sitar, T., Popowicz, G. M., Siwanow-icz, I., Huber, R., and Holak, T. A. (2006). Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc. Natl. Acad. Sci. U.S.A. 103, 13028-13033.
107. Siwanowicz, I., Popowicz, G. M., Wis-niewska, M., Huber, R., Kuenkele, K. P., Lang, K., Engh, R. A., and Holak, T. A. (2005). Structural basis for the regulation of insulin-like growth factors by IGF binding proteins. Structure 13, 155-167.
108. Song, H., Beattie, J., Campbell, I. W., and Allan, G. J. (2000). Overlap of IGF- and heparin-binding sites in rat IGF-binding protein-5. J. Mol. Endocrinol. 24,43-51.
109. Standker, L., Kubler, B., Obendorf, M., Braulke, T., Forssmann, W. G., and Mark, S. (2003). In vivo processed fragments of IGF binding protein-2 copurified with bioactive IGF-II. Biochem. Biophys. Res. Commun. 304, 708-713.
110. Suikkari, A. M., and Baxter, R. C. (1992). Insulin-like growth factor-binding protein-3 is functionally normal in pregnancy serum. J. Clin. Endocrinol Metab. 74, 177-183.
111. Sung, M., Jeong, M. S., and Jang, S. B. (2010). Biological characterization and structure based prediction of insulin-like growth factor binding protein-5. Biochem. Biophys. Res. Commun. 403, 230-236.
112. Twigg, S. M., and Baxter, R. C. (1998). Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J. Biol. Chem. 273, 6074-6079.
113. Twigg, S. M., Kiefer, M. C., Zapf, J., and Baxter, R. C. (1998). Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domain. J. Biol. Chem. 273, 28791-28798.
114. Ueki, I., Ooi, G. T., Tremblay, M. L., Hurst, K. R., Bach, L. A., and Boisclair, Y. R. (2000). Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system. Proc. Natl. Acad. Sci. U.S.A. 97, 6868-6873.
115. Vajdos, F. F., Ultsch, M., Schaffer, M. L., Deshayes, K. D., Liu, J., Skel-ton, N. J., and De Vos, A. M. (2001). Crystal structure of human insulin-like growth factor-1: detergent binding inhibits binding protein interactions. Biochemistry 40, 11022-11029.
116. Van Lonkhuyzen, D. R., Hollier, B. G., Shooter, G. K., Leavesley, D. I., and Upton, Z. (2007). Chimeric vitronectin:insulin-like growth factor proteins enhance cell growth and migration through co-activation of receptors. Growth Factors 25, 295-308.
117. Wang, G. K., Hu, L., Fuller, G. N., and Zhang, W. (2006). An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha 5 is essential for IGFBP2-induced cell mobility. J. Biol. Chem. 281, 14085-14091.
118. Wheatcroft, S. B., and Kearney, M. T. (2009). IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol. Metab. 20, 153-162.
119. Williams, R. M., Mcdonald, A., O'Savage, M., and Dunger, D. B. (2008). Mecasermin rinfabate: rhI GF-I/rhIGFBP-3 complex: iPLEX. Expert Opin. Drug Metab. Toxicol. 4, 311-324.
120. Xu, Q., Yan, B., Li, S., and Duan, C. (2004). Fibronectin binds insulin-like growth factor-binding protein 5 and abolishes Its ligand-dependent action on cell migration. J. Biol. Chem. 279, 4269-4277.
121. Yakar, S., Rosen, C. J., Beamer, W G., Ackert-Bicknell, C. L., Wu, Y., Liu, J. L., Ooi, G. T., Setser, J., Frystyk, J., Boisclair, Y. R., and Leroith, D. (2002). Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110, 771-781.
122. Yan, X., Forbes, B. E., McNeil, K. A., Baxter, R. C., and Firth, S. M. (2004). Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation. J. Biol. Chem. 279,53232-53240.
123. Yan, X., Payet, L. D., Baxter, R. C., and Firth, S. M. (2009). Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes. Endocrinology 150, 4968-4976.
124. Zeslawski, W., Beisel, H. G., Kamionka, M., Kalus, W., Engh, R. A., Huber, R., Lang, K., and Holak, T. A. (2001). The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5. EMBO J. 20, 3638-3644.